# A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Study · id `cardio:ct-nct01733758` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01733758](<https://clinicaltrials.gov/study/NCT01733758>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01733758

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.

## Technical summary

Registry record NCT01733758. Randomized; double masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-05-18.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 494 participants (enrolled count; ClinicalTrials.gov record NCT01733758, source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)
- Start date: 2013-02 (registry gives no type) (ClinicalTrials.gov record NCT01733758, source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01733758, source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01733758, source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)
- Results first posted: 2015-05-18 (ClinicalTrials.gov record NCT01733758, source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01733758, source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01733758-2016-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Albiglutide 30 mg weekly
- Intervention (Drug): Albiglutide 50 mg weekly
- Intervention (Drug): Placebo
- Intervention (Drug): Liraglutide 0.9 mg daily
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 1fccb70c342c6d233a91e15618cf2f0a3191ecc8cb80968fd6c5f38f535def2e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
